Although GSTP1 has such promising features as a cancer-specific biomarker, it has not yet been applied in a clinical setting; although the specificity of GSTP1 promoter hypermethylation is much higher than that of prostate-specific antigen (PSA), the sensitivity of GSTP1 is lower than that of PSA [14]. The gene discussed is GSTP1; the disease is cancer.